July 26, 2016 7:57 AM ET


Company Overview of KaloBios Pharmaceuticals, Inc.

Key Executives for KaloBios Pharmaceuticals, Inc.

NameBoard RelationshipsTitleAge
Cameron Durrant M.D., MBA58 RelationshipsChairman, Chief Executive Officer, Chairman of Audit Committee, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee55
Dean Witter IIINo RelationshipsInterim Chief Financial Officer68
Morgan Lam No RelationshipsChief Operating Officer51
Charles J. Democko No RelationshipsSenior Vice President of Regulatory Affairs and Quality61

KaloBios Pharmaceuticals, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Cameron Durrant M.D., MBA 58 RelationshipsKaloBios Pharmaceuticals, Inc.55
James W. Larrick M.D., Ph.D. 39 RelationshipsKaloBios Pharmaceuticals, Inc.--
Ronald Barliant 5 RelationshipsKaloBios Pharmaceuticals, Inc.--
Dale Chappell 5 RelationshipsBlack Horse Capital Advisors LLC--
Timothy Morris 5 RelationshipsKaloBios Pharmaceuticals, Inc.--
View All Board Members

KaloBios Pharmaceuticals, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee M.D., MBACameron Durrant58 Relationships2 Executives
Compensation Committee M.D., MBACameron Durrant58 Relationships2 Executives
Nominating Committee Ronald Barliant5 Relationships2 Executives
Corporate Governance Committee Ronald Barliant5 Relationships2 Executives
Advisory Board M.D., Ph.D.James W. Larrick39 Relationships1 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Total Short Term Compensation
Total Value of Options
Compensation as of Fiscal Year
KaloBios Pharmaceuticals, Inc. CEO Compensation
Industry Average


Cleveland BioLabs, Inc. Announces Executive Changes
July 22, 2016 8:22 PM ET
TetraLogic Pharmaceuticals Corporation Announces Resignation of Douglas Reed as M. D, Effective July 21, 2016
July 22, 2016 8:18 PM ET
Immunicum AB Appoints Peter Suenaert as Chief Medical Officer
July 22, 2016 10:20 AM ET
ContraFect Corporation Appoints Steven C. Gilman as President and Chief Executive Officer
July 21, 2016 9:32 PM ET
William R. Ringo Intends to Resign from Mirati Therapeutics, Inc.'s Board of Directors
July 21, 2016 8:03 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KaloBios Pharmaceuticals, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.